Cargando…

Estimated costs of production and potential prices for the WHO Essential Medicines List

INTRODUCTION: There are persistent gaps in access to affordable medicines. The WHO Model List of Essential Medicines (EML) includes medicines considered necessary for functional health systems. METHODS: A generic price estimation formula was developed by reviewing published analyses of cost of produ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hill, Andrew M, Barber, Melissa J, Gotham, Dzintars
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859811/ https://www.ncbi.nlm.nih.gov/pubmed/29564159 http://dx.doi.org/10.1136/bmjgh-2017-000571

Ejemplares similares

Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List
por: Gotham, Dzintars, et al.
Publicado: (2019)

Production costs and potential prices for biosimilars of human insulin and insulin analogues
por: Gotham, Dzintars, et al.
Publicado: (2018)

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries
por: Barber, Melissa J., et al.
Publicado: (2020)

Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis
por: Hill, Andrew, et al.
Publicado: (2017)

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C
por: Hill, Andrew, et al.
Publicado: (2016)

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
por: Hill, Andrew, et al.
Publicado: (2015)

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
por: Hill, Andrew, et al.
Publicado: (2016)

Monographs for medicines on WHO’s Model List of Essential Medicines
por: Roth, Lukas, et al.
Publicado: (2018)

A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines
por: Mustafa, Asma Abubakr, et al.
Publicado: (2010)

Patent pooling to increase access to essential medicines
por: Burrone, Esteban, et al.
Publicado: (2019)

The duration of cost-cutting effects of price-lists
por: Schilling, Ulf Martin
Publicado: (2010)

Revising the WHO Essential Medicines List for paediatric rheumatology
por: Scott, Christiaan, et al.
Publicado: (2021)

Cell line access to revolutionize the biosimilars market
por: Gotham, Dzintars
Publicado: (2018)

Revising the WHO Essential Medicines List for paediatric rheumatology update
por: Slamang, Waheba, et al.
Publicado: (2022)

Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists
por: Jarvis, Jordan D., et al.
Publicado: (2019)

Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability
por: Husain, Muhammad Jami, et al.
Publicado: (2020)

Cutting costs – the impact of price-lists on the cost development in the emergency department
por: Schilling, Ulf Martin
Publicado: (2009)

Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?
por: Hill, Andrew, et al.
Publicado: (2018)

Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)
por: Zheng, Fangfang, et al.
Publicado: (2018)

Correction to: Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability
Publicado: (2020)

Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO
por: Piggott, Thomas, et al.
Publicado: (2022)

NOACs Added to WHO’s Essential Medicines List: Recommendations for Future Policy Actions
por: Di Cesare, Mariachiara, et al.
Publicado: (2020)

Essential medicines for mental disorders: comparison of 121 national lists with WHO recommendations
por: Todesco, Beatrice, et al.
Publicado: (2023)

Back to the ‘essence’ of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines
por: Eniu, Alexandru, et al.
Publicado: (2016)

The “Square Box”: Therapeutic Equivalence as a Foundation of the WHO Model List of Essential Medicines
por: Cappello, Bernadette, et al.
Publicado: (2020)

Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
por: Sinha, Pranay, et al.
Publicado: (2022)

Using the WHO Essential Medicines List to Assess the Appropriateness of Insurance Coverage Decisions: A Case Study of the Croatian National Medicine Reimbursement List
por: Jeličić Kadić, Antonia, et al.
Publicado: (2014)

Contextual Pricing: The Death of List Price and the New Market Reality
por: Docters, Robert
Publicado: (2011)

Availability, prices and affordability of essential medicines in Haiti
por: Chahal, Harinder Singh, et al.
Publicado: (2013)

A quantitative comparison of essential cardiovascular medicines from countries in the Southern African Development Community to the WHO model essential medicines list
por: Naicker, Ian, et al.
Publicado: (2022)

National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis
por: Peacocke, Elizabeth F., et al.
Publicado: (2022)

Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021
por: Zhou, Yue, et al.
Publicado: (2023)

Priority Medicines for Maternal and Child Health: A Global Survey of National Essential Medicines Lists
por: Hill, Suzanne, et al.
Publicado: (2012)

Evaluating availability and price of essential medicines in Boston area (Massachusetts, USA) using WHO/HAI methodology
por: Sharma, Abhishek, et al.
Publicado: (2016)

Comparison of essential medicines lists in 137 countries
por: Persaud, Nav, et al.
Publicado: (2019)

The case for levetiracetam to be included in essential medicine lists
por: Singh, Gagandeep, et al.
Publicado: (2023)

Bridging the gap? Local production of medicines on the national essential medicine lists of Kenya, Tanzania and Uganda
por: Baldeh, Ayo-Oley, et al.
Publicado: (2023)

Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019
por: delMoral-Sanchez, Jose-Manuel, et al.
Publicado: (2020)

Assessing the Appropriateness of Formulations on the WHO Model List of Essential Medicines for Children: Development of a Paediatric Quality Target Product Profile Tool
por: Walsh, Jennifer, et al.
Publicado: (2022)

Withdrawn medicines included in the essential medicines lists of 136 countries
por: Charles, Onella, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1b3vu583e3i71upb44rh28gohe